Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pionyr was founded in 2015 by a UCSF professor and a Genentech alum. Source: BioSpace You Might Also Like Safety Issues Force the FDA to Turn Down Amgen, UCB SA's Osteoporosis Drug July 16, 2017 Growing Catalent Takes Out Cook Pharmica in $950 Million Deal September 18, 2017 Auris Med Announces Receipt Of Nasdaq Notice August 24, 2017
